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Lactation Post-pregnancy
3 mo 6 mo P* Baseline 2 PÎ
Spine
Femoral neck 
Whole body
-3-37 (0*81) 
-0-54 (1-03) 
-0-75 (0-41)
-3-14 (0-88) 
-2-77 (0-95) 
-1-16(0-41)
0-001
0-018
0-030
+ 0-92(0-95) 
-0-53(1-22) 
+ 0-09(0-49)
0-36
0-68
0 8 6
Data are percent change (mean (SEI) in bone mineral content adjusted for bone area* 
from baseline 1 for 12 women. *ANOVA examining effect of stage of lactation within 
individuals. tPaired t-test comparing baseline 1 arid baseline 2.
Percent changes in bone mineral status during lactation and 
after pregnancy
femoral neck was done at 2 weeks (baseline 1), 3 and 6 
months post-partum, and 2 weeks after the subsequent birth 
(baseline 2). Additional measurements were made at 12 
months post-partum and 3 months post-lactation unless the 
woman had already conceived. At enrolment, the women 
averaged 33 (SD 3) years, parity 1'2 (SD 0*4), height 1*66 
(SD 0*06) m, weight 69*6 (SD 11-5) kg, and had a calcium 
intake of 39*9 (SD 14*3) mmol daily (1590 [SD 570] g 
daily). All the women breastfed for at least 3 months* five for 
more than 9 months. The birth interval averaged 23 (SD 7) 
months. Five women conceived while lactating, three within
2 months of the 6-month bone measurement.
Lactation was associated with a significant decrease in 
bone mineral status (table). However, there was no 
significant difference between baseline 1 and baseline 23 
indicating that the bone loss had recovered before or during 
the subsequent pregnancy (table). For the nine mothers who
<
conceived after 12-months post-partum, recovery had taken 
place in later lactation or in the post-lactation period: there 
were no significant differences in bone mineral status 
between the measurement before conception and those at 
baseline 1 or 2 at any site (difference <0*8% and p>0*3 in all 
cases). However, for the three women who conceived soon 
after the 6-month measurement while still lactating, 
restoration of bone mineral status occurred during 
pregnancy itself (change between 6 months and baseline 2: 
spine=+2*0%, SE 006% , p=0*02; femoral neck=+4*3%, SE 
0-12%, p=0*02; whole body=+l*3%, SE 0-6%, p=0-26). 
One mother continued to lactate throughout her subsequent 
pregnancy without any apparent detriment to her bone 
mineral status.
Our study shows that, although significant decreases in 
bone mineral occur during breastfeeding, these changes are 
reversible and do not persist after a subsequent pregnancy. 
This appears to be the case even when conception occurs 
during lactation at a time when bone loss is still evident. 
Thus, extended periods of breastfeeding and closely spaced 
pregnancies are unlikely to have a lasting effect on the bone 
mineral status and osteoporosis risk of healthy well- 
nourished women.
This study was jointly funded by the Medical Research Council and the 
Sainsbury Charitable Fund.
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Marker for liver damage in neonates 
bom to mothers with HELLP 
syndrome
Maarten Knapen, Floor van Schaljk, Theo Mulder,
Wilbert Petersr Eric Steegers
The syndrome of haemolysis, elevated liver enzymes and low 
platelets (HELLP) is a major cause of maternal and 
perinatal morbidity and mortality,1 The aetiology and the 
characteristic pattern of maternal hepatic damage in this 
condition are not known, Deterioration of the mothers’ 
condition is a major determinant of the management of 
these pregnancies, and often results in assisted delivery of a 
premature infant. Little is known about the consequences of 
this disorder in the neonate. Thrombocytopenia has not 
been shown in neonates born from hypertensive pregnancies 
with associated maternal thrombocytopenia,"
Plasma glutathione S-transferase alpha 1-1 (GSTA1-1) is 
a sensitive indicator of hepatocellular damage in various 
hepatic disorders3 and the HELLP syndrome.4 To assess 
possible fetal hepatic damage we measured GSTA1-1 
concentrations in maternal blood plasma and corresponding 
neonatal arterial umbilical plasma samples in nine 
pregnancies complicated by the HELLP syndrome1 and in
11 uncomplicated normotensive pregnancies. All 
pregnancies resulted in caesarean section.
Plasma GSTA1-1 concentrations were measured by an 
enzyme-linked immunosorbent assay, with an anti-human 
GSTA mouse monoclonal as catching antibody, and rabbit 
anti-human GSTA antiserum as the source of detecting 
antibodies.4 The assay has no cross-reactivity with other class 
GSTs and the variations within and between assays were 
2*5% and 7-3%, respectively. Groups of individuals were 
compared with the Wilcoxon-Mann-Whitney-U test.
Maternal plasma GSTA 1-1 concentrations were much 
higher in patients than in controls (median 37*7 and 1-3 
jxg/L, respectively^ p<0*0001; figure). By contrast, babies 
born to mothers with HELLP showed similar plasma 
GSTA1-1 concentrations to those bom to controls (4-2 and 
5*9 fig/L, respectively). These results suggest that in HELLP 
syndrome, hepatocellular damage occurs only in die mother, 
and there is no evidence for neonatal hepatic damage. Toxic 
substances, oxygen radicals* or humoral factors may cause 
die maternal disease and endothelial damage.5 Since we
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found no evidence of hepatocellular damage in neonates 
born from pregnancies complicated by the HELLP 
syndrome, these substances either do not seem to cross the 
fetoplacental barrier, or the fetus may not be susceptible to 
their effects,
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Vascular endothelial growth factor 
in diabetic retinopathy
Yoshikazu Tanaka, Satoshi Katoh, Sadao Hori,
Masakazu Miura, Hidetoshi Yamashita
New-vessel formation in diabetic retinopathy is regulated by 
various angiogenic molecules. Vascular endothelial growth 
factor (VEGF) is involved in intraocular neovascularisation 
caused by retinal ischaemia* including diabetic retinopathy,1 
The concentration of VEGF in intraocular fluid in patients 
with diabetes has been reported to be increased in 
proliferative diabetic retinopathy. There is a correlation 
between expression of VEGF and blood-retinal barrier 
breakdown in the streptozotocin-induced experimental 
diabetic rat retina.2
VEGF concentration in anterior chamber aqueous humor 
of the eyes in 55 patients with diabetes and five without 
diabetes was measured with ELISA (Quantikine Human 
VEGF Immunoassay kit* R&D system* MN> USA). 37 
patients had non-proiiferative diabetic retinopathy, nine had 
active proliferative retinopathy* and nine had quiescent 
proliferative retinopathy. Aqueous humor was obtained 
during cataract surgery after securing permission from 
patients. VEGF concentrations were compared with grade of 
diabetic retinopathy* retinal vessel barrier function evaluated 
by fluorescein angiography, duration of diabetes, blood 
glucose control (HbAlc)* and protein concentration in 
aqueous humor. Aqueous protein concentration is an 
indicator of blood-ocular barrier function and is measured 
with a laser-flare cell meter.3
Multivariate regression analysis showed that VEGF 
concentration was significantly correlated with the grades of 
retinopathy and the protein concentration in aqueous 
humor. Mean concentration of VEGF in active proliferative 
diabetic retinopathy patients was 0*47 (SD 0-49) ng/mL; 
significantly higher than in non-diabetic patients* in patients 
with non-proliferative retinopathy) or with quiescent 
proliferative retinopathy: 0*09 (0*06) ng/mL, 0*11 (0*09) 
ng/mL* and 0*24 (0110) ng/mL. In patients with non­
proliferative retinopathy* VEGF concentrations tended to be 
higher when duration of diabetes was longer (correlation 
coefficient=0'31). VEGF concentration was higher in the 
eyes of patients with non-proliferative retinopathy compared 
with undamaged eyes (0*20 [0*13] ng/mL, six eyes vs 0-12 
[0*05] ng/mL, seven eyes* p<0*01).
These results suggest that agents blocking VEGF may be 
useful to prevent progression of retinal vessel damage in 
diabetic retinopathy.
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BCG vaccine in insulin-dependent 
diabetes mellitus
Pao/o PozzilU on behalf of the IMDIAB Group*
In 1994, Shehadeh and colleagues1 reported in this journal 
that a single injection of Bacille Calmette Guerin (BCG) 
vaccine induced clinical remission in 65% of recent-onset 
insulin-dependent diabetes mellitus (IDDM) patients 
compared with 7% of controls. The number of patients 
included in that pilot trial was small (17). A commentary in 
the same issue concluded that a large trial should be 
undertaken without delay.2 Following previous trials aimed at 
increasing the remission rate in patients with recent-onset 
IDDM  with several different approaches,-1’*1 the IMDIAB V 
triai was set up to test the effect of BCG.
This was a randomised multicentre trial in 72 newly 
diagnosed IDDM  patients (duration of disease less than 4 
weekSj mean age 14-5 years, SD 6) aimed at comparing the 
effect of BCG plus nicotinamide (NCT) (25 mg per kg 
bodyweight) to that of the same dose of NCT alone. The 
number of patients to be included in the study was calculated 
assuming a 65% remission rate in the BCG-treated group1 
and a 28% remission rate in the NCT group (the latter 
calculated from data presented in refs 3 and 4)* setting alpha 
equal to 0-05 and beta equal to 90%. The vaccine was 
administered at ID D M  diagnosis in the forearm in one single 
intracutaneous dose of 0*1 mL freeze-dried BCG vaccine 
(Berna Institute* Basel) after reconstitution with buffered 
saline to a final concentration of 1 mg/mL. All patients 
underwent intensive insulin therapy with three to four insulin 
injections a day as described in our previous studies.3,4
Results of metabolic control (insulin dose, C-peptide, 
glycosylated haemoglobin) at 3, 6* 9* and 12 months after 
diagnosis are shown in the table. No significant differences 
were seen between the two groups of patients. With the 
criteria for clinical remission reported by Shehadeh et al1 
(<0’2 IU of insulin with fasting and post-prandial blood 
glucose below 8*3 and 11*1 mmol/L* respectively)* the 
BCG +NCT group did not differ from the group treated with 
N C T  in the rate of clinical remission (41% vs 46%, 
respectively). The length of remission was also similar 
between the two groups, Furthermore, these values of 
remission are within the expected rates even in patients 
receiving intensive insulin treatment without any other 
adjuvant therapy.
In conclusion* our data do not support the finding that 
BCG vaccination induces long-term clinical remission in 
patients with recent-onset IDDM. However, it should be 
underlined that, in our study* the efficacy of the BCG vaccine
*Members of IMDIAB group are listed in references 3 and 4
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